Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
Date:5/15/2008

XI'AN, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that there was no damage incurred to their facilities as a result of the Sichuan Earthquake.

Immediately following the earthquake, local Xi'an government officials ordered all workers sent home. However, the company is pleased to announce that the Government has since allowed the workers to return to the facilities and operations have resumed with only a minimal delay to production.

''We are terribly saddened by the loss of life and property in the Sichuan Earthquake. While we are happy to report that neither our employees nor our facilities suffered any harm, Huifeng is prepared to provide support to the victims of this terrible disaster,'' stated company CEO Jing'An Wang. ''As of this time, operations at Huifeng have returned to normal and all employees are back at work.''

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

For more information, please contact:

Dan Carlson,

Primary Capital LLC

'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
5. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... Sept. 2, 2015 Australian prostate cancer technology ... Australian science prize recognising ,outstanding, science that uses its ... globally launch a novel prostate cancer diagnostic test known ... level consortium taking out the peer-reviewed Australian Museum Eureka ... This prize is awarded for ground ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... of researchers has proposed a way to turn the material ... of electrons with a laser "on-off switch". Graphene is ... carbon atoms only one-atom thick, but 200 times stronger than ... than any other known material. It is almost completely transparent, ...
... June 17, 2011 Kendle International Inc. (Nasdaq: ... increased the consideration amount offered for its cash tender ... its $142.5 million aggregate principal amount of outstanding 3.375% ... No. US48880LAA52) (the "Notes").  The consideration for each $1,000.00 ...
... have been proposed for cell-based diagnostics and regenerative medicine ... develop into a desired cell type -- such as ... the clinical potential of these technologies. New research ... of the International Society for Stem Cell Research (ISSCR) ...
Cached Biology Technology:Graphene may gain an 'on-off switch,' adding semiconductor to long list of material's achievements 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/26/2015)... August 26, 2015 The report "Multi-Factor ... Five Factor), Application (Travel & Immigration, Government, Banking, Defense, ... Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market ... growing at a CAGR of 17.7% between 2015 and ... F igures spread through 169 P ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... presented at IAS build a compelling case for FUZEON ... the newest drugs to give patients facing resistance their ... treatment goal for all people living with HIV. , ... for all triple-class experienced patients. FUZEON combined with the ...
... A computer scientist at Washington University in St. Louis ... genome of a worm and has found 150 genes ... using the software, he and his colleagues have developed ... genes. , Michael Brent, Ph.D., Washington University professor of ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Newest HIV drugs should be used with FUZEON(R) 2Newest HIV drugs should be used with FUZEON(R) 3Program finds lost genes in nematode genome 2Program finds lost genes in nematode genome 3Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
... Clone/PAD: ZMD.366. Immunogen: ... internal region of human SENP1. ... human ~73 kDa SENP1. ... or DYKDDDDK)-HA-tagged-SENP1 transfected Hep2 cell ...
...
Biology Products: